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ABSTRACT
This study aimed to evaluate the long term impact of a new pharmacological class antihypertensive medicine-angiotensin II
antagonist (AIIA) on the clinical utilization of existing antihypertensive medications in Taiwan. Claims data of medical service
and prescriptions of antihypertensive agents during 1997 to 2002 were obtained from National Health Insurance Research Database
(NHIRD). Gross growth of defined daily dose (DDD) and prescription numbers, clinical market share and prescription market share
analysis, market penetration time and DDDs/prescription were used to assess AIIA’s impact on the angiotensin converting enzyme
inhibitors (ACEI), ß-Blockers, calcium channel blockers (CCB) and other miscellaneous antihypertensive agents. CCB had the
highest gross growth of DDDs and prescription at 117.1 and 3.4 million increments, respectively. Analysis of clinical market share
revealed that the introduction of AIIA had the most significant impact to the clinical utilization of miscellaneous antihypertensive
agents (-5.5%) and a moderate impact on both ß-blockers (-4.5%) and ACEI (-4.1%). Whereas the greatest impact of prescription
market share was observed with miscellaneous antihypertensive agents (-6.5%), a moderate impact with ACEI (-2.3%) and a very
minor impact with ß-blockers (-0.9%). CCB, however, had a positive clinical market share (+3.9%) and prescription market share
(+2.4%) correlated with AIIA. AIIA utilization implicated by relative growth strength for the clinical market share and prescription
market share at medical center, regional hospital, district hospital and primary care clinic were 4.95:3.77:2.77:1 and 5.28:4.17:2.94:1,
respectively. The introduction of AIIA did not affect the decreasing trend of clinical utilization of miscellaneous antihypertensive
agents and ß-blockers since this downtrend started before AIIA introduction. On the other hand, there was increasing usage of CCB
and AIIA to control hypertension in Taiwan. Medical centers were the early adaptors for AIIA and played an important role in the
utilization diffusion of AIIA.
Key words: angiotensin II antagonist (AIIA), angiotensin converting enzyme inhibitor (ACEI), ß-blocker, calcium channel blocker
(CCB), defined daily dose (DDD), market share, drug utilization

INTRODUCTION
Cheng and Hsieh reported that the average annual
growth rate on Taiwan’s total National Health Insurance drug expenditure was 6.4% from 1996 to 2002(1).
The drug expenditure on the cardiovascular medications
between 1997 and 2002 more than doubled from 5.89
billion NTD to 11.90 billion NTD, at an annual growth
rate of 19.9%(2). This indicated that the rate of the cardiovascular drug expenditure in Taiwan grew at almost
twice faster than that of the average drug expenditure.
It also grew at a much faster rate than Canada (10.4%
annual rate in 1999 to 2003), where similar national
* Author for correspondence. Tel: +886-6-2353535 ext. 5688;
Fax: +886-6-2373149; E-mail: yhkao@mail.ncku.edu.tw

health insurance program was implemented(3).
Pharmacologically, antihypertensive agents are classified into the following groups: diuretics, ß-blockers, ACE
inhibitors (ACEI), calcium channel blockers (CCB), angiotensin II receptor blockers (AIIA), α-blockers, central α2agnonists, adrenergic inhibitors, and vasodilators. AIIA is
a new pharmacological class of antihypertensive medication introduced into Taiwan’s market in the first quarter of
1998. Before its introduction, the antihypertensive medication market could be divided into four segments by their
pharmacological classes: ACEI, ß-blockers, CCB, and
other miscellaneous antihypertensive agents. Based on
the available evidences including the results of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
Attack Trial (ALLHAT), thiazide diuretics are recom-
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mended as the initial therapy for patients with uncomplicated hypertension. A ß-blocker without intrinsic sympathomimetic activity is suggested to be given after an acute
myocardial infarction. And, a greater efficacy of the CCBs
and diuretics in elderly and black hypertensive patients has
also been documented. In addition, ACEI is found effective in patients who have heart failure, myocardial infarction, diabetes or proteinuric chronic renal failure. AIIAs
and ACE inhibitors are likely to have similar indications
and efficacy(4,5), but AIIA is particularly for patients who
develop cough with ACEI(6,7). Note that lowering blood
pressure is not the sole consideration in selecting antihypertensive medication. Instead, the compelling indications, tolerability and cost effectiveness should be all taken
for justification in prescribing decisions.
As more clinical data become available, AIIA gradually gains acceptance among the physicians as the firstline treatment. AIIA, with approximately 60% pricing
premium over the average price of all antihypertensive
drugs, would impact both total drug expenditure and
drug utilization shift. It is thus worth the effort to investigate how AIIA would affect the existing drug utilization and the physicians’ prescribing behaviors using the
time trend analysis before and after AIIA introduction of
antihypertensive prescription patterns.
Retrospective pharmacoeconomic analysis using
claim database is commonly used to compare health
costs associated with competing drugs or intervention(8).
In this study, we took the 1997-2002 ambulatory service
records and prescription claim data file from the NHIRD
to analyze the utilization trend of ACEI, ß-blockers,
CCB and miscellaneous antihypertensive agents before
and after the introduction of AIIA in Taiwan, in order to
better understand how a new and innovative pharmacological class of medication may influence the utilization
of the existing medications.

MATERIALS AND METHODS
I. Data Collection
With the launch of the National Health Insurance
Program in 1995, Taiwan’s healthcare system is publicly managed by the Bureau of National Health Insurance
(BNHI) and covers 22 million people (98.7% of the total
population) by the end of 2003. The BNHI contracted
with 17,022 (93.8%) medical institutions nationwide (9).
Medical institutions are classified into four levels by
their service capacity: medical center (MC), regional
hospital (RH), district hospital (DH) and primary care
clinic (PCC). All hospital settings provide both inpatient hospitalization service and outpatient ambulatory
care service. Patients can choose between primary care
clinic and outpatient service of any medical institution
with tiered registration fee and co-payment. The outpatient prescription drug expenditure is covered by BNHI

as part of the benefit package. The national claims data
became available since 1997 which was the first time the
public could access such detailed database. This claims
database, called National Health Insurance Research
Database (NHIRD), is managed by the National Health
Research Institute (NHRI), a non-profit research organization founded and sponsored by the Department of
Health. Special request to use the NHIRD data has to be
reviewed and approved beforehand.
All ambulatory antihypertensive medications used
in Taiwan during 1997 to 2002 were obtained from the
NHIRD, which included ambulatory service records and
prescription details. Both files were merged by patients’
encrypted identification codes with an average matching
of 99.6% and a total of 122,397,631 observed data sets
for 6,228,094 patients. A total of 1021 antihypertensive
products were included for analysis, which was identified from the NHI pharmaceutical reimbursement database. The data were subsequently grouped by Anatomical Therapeutic Chemical (ATC) classification system
using the National Health Insurance Pharmaceutical
Coding System previously developed by Yang Kao (10).
Based on this Coding System, the consumption of drugs
was computed by defined daily doses (DDDs), which was
the assumed average maintenance dose per day for a drug
used for its main indication in adults. According to the
ATC system, the antihypertensive agents were classified
into the following categories：centrally acting antiadrenergic agents (C02A), peripherally acting antiadrenergic
agents (C02C), antihypertensives and diuretics in combination (C02L), agents acting on arteriolar smooth muscle
(C02D), combinations of antihypertensives in ATC group
C02 (C02N), low-ceiling diuretics, thiazides (C03A), lowceiling diuretics, excluding thiazides (C03B), high-ceiling diuretics (C03C), potassium-sparing agents (C03D),
diuretics and potassium-sparing agents in combination
(C03E), beta blocking agents (ß-blockers, C07A), beta
blocking agents and thiazides (C07B), beta blocking
agents and other diuretics (C07C), beta blocking agents,
thiazides and other diuretics (C07D), calcium channel blockers with mainly vascular effects (CCB, C08C),
calcium channel blockers with direct cardiac effects
(C08D), ACE inhibitors (ACEI, C09A), angiotensin II
antagonists (AIIA, C09C), and angiotensin II antagonists
combinations (C09D). All antihypertensive medications
except ACEI (C09A), ß-blockers (C07A), CCB (C08C)
and AIIA (C09C) are classified as miscellaneous antihypertensive agents in this study. All data were presented
in units or percentage per year.
II. Method of Analysis
Clinical market share and prescription market share
are defined as the ratio of the amount of DDDs/prescriptions claimed by individual antihypertensive category to
the total amount of DDDs/prescriptions claimed by all antihypertensive medication under ATC system, respectively.

23
Journal of Food and Drug Analysis, Vol. 16, No. 4, 2008

Clinical market share = DDDs of individual sub C
class claimed /∑ DDDs of each sub C class claimed
(1)
Prescription market share = number of prescriptions
claimed by individual sub C class /∑ number of prescriptions of each sub C class claimed
(2)
Penetration Time (PTx%) is defined as the time for
a specific medication or a class of medication to reach
x% of the market share in a specified market, namely the
medical institution.
III. Statistical Analysis
All data analysis was performed using SAS package
(Windows Release 8.02 Version TS Level 02M0) from
SAS Institute Inc. (Cary, NC, USA.). Chi-square test and
t-test were used to compare nominal and numerical variables, respectively, and data were considered statistically
significant at P < 0.05. We employed linear regression
to demonstrate the differences of clinical market share
and prescription market share among the four levels of
medical institutions. For linear regression analysis, the
least-squares method of best-fit curve was done using
the analytical tools provided by Microsoft ® Office Excel
2003 (Redmond, WA, USA.).

RESULTS
The patient profiles are summarized in Table 1. The
average age of patients taking antihypertensive medication during this period was 56.0 ± 17.2. During the 6-

year period, age 60 to 70 represented the largest patient
group with an average proportion of 23.32 ± 0.98% of the
total patient population. Female patients were more than
male ones with statistical significance (53.63 ± 0.22% vs.
45.95 ± 0.17% ; P ≤ 0.01).
I. Gross Growth of the Clinical Utilization of Antihypertensive Medications
AIIA was introduced into Taiwan in the first quarter of 1998. The overall growth of the total and five
sub groups of antihypertensive drugs’ clinical usage in
Taiwan during 1997 to 2002 in terms of drug quantity
consumed (DDDs) and number of prescriptions is shown
in Table 2. The results showed that total antihypertensive
drug quantity consumed and prescription numbers grew
by 90.9% and 47.9% in six years, respectively. The data
in Table 2 demonstrated that the growth rate of prescription number for CCB and AIIA were the highest at 64.2%
and 2600%, respectively. Furthermore, their increments
(3.4 and 2.7 millions) in prescription number accounted for 52.6% of the total increase (11.6 millions) within
six years was a major contributor to the drug quantity
prescribed. On the other hand, the nearly doubled DDDs
growth was more of a clinical factor depending on severity of the disease and physician’s medical judgment.
II. Market Share Analysis of the Clinical Utilization of Antihypertensive Medications
Due to the high gross growth for almost all antihy-

Table 1. Characteristics of patients prescribed with antihypertensive medications from 1997 to 2002
1997

1998

1999

2000

2001

2002

Patient

2,328,204

2,650,132

2,891,479

2,892,826

3,034,745

3,118,601

Patient Visits

16,073,491

19,194,467

21,206,820

20,296,332

22,024,726

23,063,913

Total mean

AGE (%)
< 40

414,412 (17.80) 465,726 (17.57) 507,675 (17.56) 469,894 (16.24) 484,845 (15.98) 480,847 (15.42)

40-49

383,671 (16.48) 452,378 (17.07) 500,516 (17.31) 498,236 (17.22) 517,125 (17.04) 517,607 (16.60)

50-59

434,194 (18.65) 492,229 (18.57) 538,858 (18.64) 546,335 (18.89) 582,624 (19.20) 616,663 (19.77)

60-69

578,475 (24.85) 636,694 (24.02) 672,446 (23.26) 667,904 (23.09) 684,372 (22.55) 691,651 (22.18)

70-79

405,667 (17.42) 469,798 (17.73) 522,931 (18.09) 549,950 (19.01) 587,262 (19.35) 613,235 (19.66)

80

111,785 (4.80)

133,307 (5.03)

149,053 (5.15)

160,507 (5.55)

178,517 (5.88)

198,598 (6.37)

Mean Age (± SD)

55.36 ± 17.50

55.51 ± 17.67

55.47 ± 17.41

56.22 ± 17.00

56.44 ± 16.91

56.75 ± 16.93

56.00 ± 17.22

Female (%)

53.79

53.80

53.79

53.68

53.48

53.26

53.63 ± 0.22*

Male (%)

45.91

45.74

45.83

45.93

46.05

46.22

45.95 ± 0.17*

Unknown (%)

0.30

0.46

0.38

0.39

0.48

0.51

Gender

*p < 0.01 by Chi-square test.
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Table 2. Utilizations of the antihypertensive drugs CCB, ACEI, ß-blockers (BB), AIIA and miscellaneous antihypertensive agents (MIS) in
Taiwan from 1997 to 2002
No. of DDDsa &
Clinical market share (%)

Year

‘97

‘98

‘99

‘00

‘01

‘02

Δ97-02

d

Clinical market share/
prescription market share
Total

CCB

ACEI

BB

AIIA

MIS

Total
DDDs

CCB

ACEI

BB

AIIA

MIS

98.1

91.5

90.2

0

92.2

372.0

5.3

3.8

6.6

0

8.5

(26.4) (24.6) (24.2)

(0)

(24.8)

(0)

(35.1)

127.2

2.9

107.3

0.1

9.7

(27.6) (25.2) (23.3)

(0.6)

(23.3)

(0.5)

(33.3)

151.2

121.2

16.2

119.3

0.7

10.3

(28.1) (24.3) (22.5)

(3.0)

(22.1)

(2.1)

(32.2)

161.2

122.4

30.7

119.1

1.2

9.6

(28.6) (23.2) (21.7)

(5.4)

(21.1)

(3.8)

(31.0)

190.2

134.7

49.9

129.5

1.8

10.1

(29.4) (22.0) (20.8)

(7.7)

(20.0)

(5.4)

(29.7)

215.2

72.2

137.3

2.7

10.2

(10.2)

(19.3)

(7.4)

(28.6)

1.25 1.53 0.75 1.37 0.68
0.05 -0.04 -0.14 -0.01 -0.03

115.8

130.8

130.8

142.0

145.9

107.1

139.5

(30.3) (20.5) (19.7)
ΔMS,97-02c

No. of prescriptionsb &
Prescription market share (%)

3.9

-4.1

-4.5

10.2

-5.5

117.1

54.4

49.3

72.2

45.1

(21.9) (15.7) (27.3)
460.3

6.6

4.7

7.8

(22.9) (16.3) (27.1)
538.7

7.3

5

8.8

(22.7) (15.7) (27.3)
564.2

7.1

4.7

8.5

(22.9) (15.0) (27.3)
646.3

8

4.8

9.2

(23.5) (14.2) (27.1)
710.1

8.7

4.8

9.4

(24.3) (13.4) (26.4)

338.1

(119.4) (59.5) (54.7) (2389.7) (48.9) (90.9)

2.4

-2.3

-0.9

7.4

-6.5

3.4

1

2.8

2.6

1.7

Pr

CCB ACEI BB AIIA MIS

24.2
1.20 1.57 0.89 N/A 0.71
28.9
1.21 1.54 0.86 1.38 0.70
32.1
1.23 1.54 0.82 1.46 0.69
31.1
1.25 1.55 0.79 1.45 0.68
33.9
1.25 1.54 0.77 1.42 0.67
35.8

11.6

(64.2) (26.3) (42.4) (2600.0) (20.0) (47.9)

a

DDDs represent the total antihypertensive drugs used in each year (in millions).
The number of antihypertensive prescriptions claimed in each year (in millions).
c
The figure indicates the difference of market share between 1997 and 2002 for each antihypertensive category.
d
The figure indicates the difference of DDDs or prescription number between 1997 and 2002 except that of AIIA is based on 1998. Figure in
parenthesis represents the growth rate.
b

pertensive medication, we transformed the absolute value
into the market share, to differentiate the relative performance of the sub groups. Clinical market share and
prescription market share data for each sub group of the
antihypertensive medication during 1997 to 2002 are also
presented in Table 2. Clinical market share was roughly
equally divided into 4 segments: ACEI, ß-blockers, CCB
and miscellaneous antihypertensive agents at 1997. The
introduction of AIIA has clearly led to decreasing clinical
utilization of ACEI, ß-blockers and miscellaneous antihypertensive agents while consumption of CCB increased.
While AIIA gained 10.2% for clinical market share,
ACEI lost only 4.1% market share. Miscellaneous antihypertensive agents lost the largest clinical market share
of 5.5%, dropping from the second position to the fourth
one, and ß-blockers lost 4.5% clinical market share, the
second largest loser next to miscellaneous antihypertensive agents. CCB gained 3.9% of clinical market and
2.4% of prescription market during this period. Miscellaneous antihypertensive agents still retained the highest
prescription market share at 2002 but lost more market
share, from 35.1% to 28.6%, than any other group. ß-

Blockers only lost a minor share of 0.9% of prescription
market share and still held the second position. Segments
of the prescription and clinical markets have been shifted
from ß-blockers, ACEI and miscellaneous antihypertensive agents to CCB and AIIA.
III. Market Share Analysis for AIIA at Different Levels of
Medical Institutional Setting
Linear regression analyses on the clinical market
share and prescription market share for AIIA at four
different medical settings from 1998 to 2002 are presented in Figure 1 and 2. The clinical market share slope for
total, MC, RH, DH and PCC was 0.0238, 0.0349, 0.0238,
0.0208 and 0.0075 with R 2 = 0.9999, 0.9973, 0.9932,
0.9998 and 0.9797, respectively. The prescription market
share slope for total, MC, RH, DH and PCC was 0.0173,
0.0280, 0.0221, 0.0156 and 0.0053 with R 2 = 0.9987,
0.9960, 0.9934, 0.9989 and 0.9741, respectively. The
relative growth strength for the clinical market share and
prescription market share at MC, RH, DH and PCC can
be obtained by dividing the slope of each medical setting
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CMS

MC

18.00%

RH

DH

PCC

y(RH) = 0.0283x - 0.0185
R2 = 0.9932

12.00%

y(Total) = 0.0238x - 0.0175
R2 = 0.9999

10.00%
8.00%

y(DH) = 0.0208x - 0.0153
R2 = 0.9998

6.00%
4.00%
2.00%

y(PCC) = 0.0075x - 0.0084
R2 = 0.9797

98

99

00

01

02

Year

Prescription market share

y(MC) = 0.0394x - 0.0213
R2 = 0.9973

14.00%

0.00%

MC

14.00%

16.00%

Clinical market share

PMS

Total

RH

DH

PCC Total

12.00%

y(MC) = 0.028x - 0.0151
R2 = 0.996

10.00%

y(RH) = 0.0221x - 0.014
R2 = 0.9934

8.00%

y(Total) = 0.0173x - 0.0136
R2 = 0.9987

6.00%

y(DH) = 0.0156x - 0.0111
R2 = 0.9989

4.00%

y(PCC) = 0.0053x - 0.006
R2 = 0.9741

2.00%
0.00%

98

99

00

01

02

Year

Figure 1. Linear regression analysis of the clinical market share
(CMS) for total AIIA and its components at different medical settings
from 1998 to 2002.

Figure 2. Linear regression analysis of the prescription market share
(PMS) for total AIIA and its components at different medical settings
from 1998 to 2002.

with that of PCC which yielded 4.65: 3.17: 2.77:1 and 5.28:
4.17: 2.94:1, respectively. This result clearly demonstrated that the market growth strength for AIIA is as follows:
MC > RH > DH > PCC.
The 5% clinical market share penetration time
(PT5%,CMS) for AIIA at MC, RH, DH are 1 year, 2 years
and 3 years; PT10%,CMS for MC and RH are 3 years and 4
years, and PT15%, CMS for MC was 4 years. The results
showed that RH had 1 to 2 years of lag behind MC to
seize another 5% clinical market share. DH also took
another 1 to 2 years than DH to acquire that extra 5%
clinical market share.

ACEI, ß-blockers, and miscellaneous antihypertensive
agents. CCB was also the only sub category, with the
exception of AIIA due to its low base at 1998, which
had more percentage growth than the whole cardiovascular medication. As for prescription growth, CCB still
had the most gain followed by ß-blockers, AIIA, miscellaneous antihypertensive agents, and then ACEI. CCB,
again, was the only sub category, with the exception of
AIIA, that had higher percentage prescription growth
than the total group. It was found that the utilization of
CCB increased after the introduction of AIIA, while that
of ACEI, ß-blockers and miscellaneous antihypertensive
agents decreased over the study period. CCB, AIIA and
ß-blockers showed a linear growth pattern for both DDDs
and prescription dimension in 1997 to 2002. ACEI and
miscellaneous antihypertensive agents were the two sub
groups that reached plateau for prescription aspects at
1999, second year after AIIA introduction, despite their
continuing DDDs growth.

DISCUSSION
I. Impact of AIIA on the Gross Growth of Antihypertensive
Medications
The total drug consumption increased in a linear
pattern. On the other hand, the prescription drugs had
a moderate growth rate which tapered off after the first
3 years. The 47.9% prescription growth was mainly due
to the intrinsic factors of patient number and patient visit
increases (34% and 43%, as derived from Table 1) during
the study period. The growth rate of prescription number
per patient visit, a clinical factor, was found to be 4%. Both
annual patient number growth and patient-visit growth
might be due to easier accessibility and growing elderly
population. Different means have been proposed and
tested to reduce this growth, including denying or limiting reimbursement of pharmaceutics through co-payment,
co-insurance or deductible and providing an incentive for
patients to reduce their consumption of drugs. However,
results indicated that such means had little effect on the
total cardiovascular drug consumption growth(11-13).
As for the individual sub cardiovascular medication, CCB had the most DDDs gain followed by AIIA,

II. Normalization of the Clinical Utilization of the Antihypertensive Medication
The gross DDDs growth was normalized with the
gross prescription growth to adjust the dual growth effect.
The total and individual sub group DDDs/prescription
data from 1997 to 2002 are shown in Table 3. The average
DDDs/prescription for the whole group in these 6 years
was 17.5 ± 1.8. The average DDDs/prescription for each
sub group was 14, 21 or 28. This result showed that the
medication prescribed in each prescription is good for 2, 3
or 4 weeks supply. The data also showed that medication
prescribed per prescription gradually increased in every
sub category of antihypertensive drugs in the study period.
Among individual sub groups, ACEI had the highest absolute average DDDs/prescription followed by
AIIA. However, there was no significant difference (P
= 0.324) between that of ACEI and AIIA based on the
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Table 3. Quantity of antihypertensive medications claimed defined daily doses per prescription (DDDs/Rx) for total and each sub group of
drugs in Taiwan from 1997 to 2002
DDDs/Rx

CCB

ACEI

BB

AIIA

MIS

Total

‘97

18.5

24.0

13.6

N/A

10.9

15.4

‘98

19.2

24.5

13.7

21.8

11.1

15.9

‘99

20.8

25.9

13.9

24.6

11.6

16.8

‘00

22.7

28.1

14.5

26.3

12.4

18.2

‘01

23.9

29.4

14.6

27.3

12.9

19.1

‘02

24.7

30.3

14.8

27.3

13.4

19.8

12.0±1.0

17.5±1.8

2.5

4.4

22.9

28.6

Year

Ave.±STD

a
b

21.6±2.5

a

27.0±2.6

14.2±0.5

a,b

25.5±2.3
b

Δ97-02

6.2

6.3

1.2

5.5

%↑97-02

33.5

26.3

8.8

25.2b

t-test was used to compare the means of DDDs/prescriptpion of ACEI and AIIA during 1997 to 2002；P＝0.324.
Figures represent the data from 1998 to 2002.

t-test, indicating that physicians in Taiwan had similar prescribing pattern in terms of the quantity of drugs
prescribed per prescription for these two pharmacological classes of medication. ACEI had the highest absolute DDDs/prescription increment during these 6 years.
AIIA had very close absolute and percentage increment
to that of ACEI. CCB had the intermediate average
DDDs/prescription but the second highest absolute increment and the highest percentage increment. ß-Blockers
and miscellaneous antihypertensive agents had lower
DDDs/prescription growth than the whole group average.
ß-Blockers had the lowest absolute DDDs/prescription
increment and percentage increment followed by miscellaneous antihypertensive agents. These data indicated
that the introduction of AIIA had a negative impact on
the clinical utilization pattern of ß-blockers and miscellaneous antihypertensive agents. This result thus suggested that both ß-blockers and miscellaneous antihypertensive agents were the less favorable antihypertensive
medications used by the physicians.
Drug co-payment scheme was first implemented in
August 1998 in Taiwan with drug co-payment ceiling
of NTD 100 per physician visit. The co-payment ceiling was further raised to NTD 200 per physician visit in
September 2002 to control drug consumption growth.
However, this intervention had little effect on the total
antihypertensive drug consumption growth due to the
DDDs per prescription growth. This result is similar
to that obtained by other researchers for the drug copayment program(12,13). It is reasonable to suspect that
the physician may prescribe more medications for the
patient to compensate for the co-payment increase.
Under previous fee-for-service reimbursement policy in
Taiwan, physicians or hospital administrators had low
incentive to change the prescribing pattern or clinical

guidelines since the physician or hospital would get full
pharmaceutical reimbursement from BNHI.
III. Comparison of Antihypertensive Utilization Using
Market Share Methodology
Market share analysis removes the intrinsic growth
factor that we faced in the gross growth analysis by focusing only on the relative product strength within its own
group. Pharmaceutical industry is a regulated field with
a very high entry barrier. Larger market share generally
means stronger market power and higher profit(14,15). Pharmaceutical companies use various means to influence the
prescribing decisions. Of these, detailing is probably the
most important way of communicating with and informing physicians about a drug’s performance. Other promotion activities include advertising in medical journals,
annual conference at medical association, direct mail,
post-marketing research (PMR) programs, and continuing medical education (CME) events(16). The main market
share determinants in these highly regulated industries are
government regulation, competitors’ pricing, advertisement, and promotion(17,18). Therefore, using the market
share analysis as an indicator to reflect both the clinical performance and promotion campaigns allows us to
compare the utilization trend among the different pharmacological classes of the antihypertensive medications.
AIIA, with remarkable increase in market share,
shows no sign of slowing growth. In the US, AIIA use
among hypertensive adults had reached 9.0% during 1999
to 2002(19). AIIA shares similar pharmacologic effect
with ACEI with less cough side effect. It was expected
that AIIA would gradually replace ACEI. However, the
10.2% clinical market share or 7.4% prescription market
share growth of AIIA could not totally account for the
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substitution of ACEI (4.1% and 2.3% loss, respectively).
Actually, the combined market share of ACEI and AIIA
increased over this 6-year period. It is quite clear that
the growing clinical and prescription market share of
AIIA is mainly from the loss of ß-blockers and miscellaneous antihypertensive agents. Furthermore, CCB utilization was raised concurrently with AIIA, and both the
clinical market share and prescription market share were
increased by 3.9% and 2.4%, respectively. This finding
indicated that the antihypertensive regimen adopted by
physicians in Taiwan had gradually changed.
Clinical market share, reflecting the physicians’
preference, is a quantity indicator for the clinical utilization of a specific product or a sub group for the treatment
of a disease or symptom(14,15). By tracking the clinical
market share trend for each sub class, we observed that
ACEI continued to gain physicians’ support at the first
year of AIIA’s introduction until 1999, 2nd year after
AIIA’s introduction. The rate of ACEI switching to other
medication was gradually accelerating over the next 4
years, dropping from 25.2% at 1998 to 20.5% at 2002. ßBlockers and miscellaneous antihypertensive agents lost
4.5% and 5.5% of clinical market share over the study
period at a fluctuating but decreasing rate. Both categories lost clinical market share even before the introduction of AIIA, indicating that utilization of both groups
were at downtrend before AIIA’s introduction. AIIA and
CCB gained physicians’ preference for the antihypertensive treatment with a 10.2% and 3.9% clinical market
share growth at the expense of ACEI, ß-blockers and
miscellaneous antihypertensive agents.
However, clinical market share suffers from various medical factors such as severity of the disease and
social factors such as duration of prescription period paid
by the insurance company. Because specific drugs must
get into the prescribing physician’s mind first, prescription market share is more of a clinical preference indicator
and provides another aspect for drug utilization analysis.
Namely, prescription market share is more dependent upon
the physicians’ prescribing favorites than clinical market
share, while clinical market share deals with the quantity
of medication prescribed. The latter would be dependent
on the severity of the disease and the physicians’ prescribing pattern. By comparing the clinical market share and
prescription market share for AIIA, it is understandable
why longer time is needed to penetrate the prescription
market than the clinical market. For example, 5% of clinical market share and prescription market share of AIIA
was reached at 2000 and 2001, respectively. 10% of clinical
market share of AIIA was reached at 2002 while only 7.4%
of prescription market share was reached at the same year.
IV. Variations of the Utilization Trends among Antihypertensive Agents
Higher clinical market share/prescription market
share value usually means more favorable choices among

physicians because they tend to prescribe more DDDs per
prescription while lower clinical market share/prescription market share value means un-favorable choices for
the physicians. Clinical market share/prescription market
shares for ß-blockers and miscellaneous antihypertensive
agents were less than 1 even before the introduction of
AIIA while that of ACEI, AIIA and CCB were more than
1 (Table 2). ACEI had the highest and relatively stable
but declining clinical market share/prescription market
share ratio during the study period. AIIA had the second
highest but fluctuating clinical market share/prescription market share ratio. CCB also had a relative stable
but rising clinical market share/prescription market share
ratio. ß-Blockers, on the other hand, lost the highest
clinical market share/prescription market share ratio. It
is interesting to note that, even though ACEI, ß-blockers
and miscellaneous antihypertensive agents all lost market
shares with the decreased clinical market share/prescription market share ratio; none of them had similar patterns.
ß-Blockers lost very small prescription market share but
larger clinical market share and thus had the most clinical
market share/prescription market share loss. This means
that even though ß-blockers still remains in the treatment regimen but has the lowest absolute and percentage
DDDs/prescription growth (at 1.2; 8.8%, respectively, see
Table 3). Physicians may simply add additional medications such as CCB or AIIA to the treatment regimen to
control the hypertension. It seems that ß-blockers will
probably stay in the physicians’ prescription list based
on the high prescription market share value at the end of
the study period. As for the miscellaneous antihypertensive agents, it lost similar significant portion on clinical
market share and prescription market share and thus had
very little clinical market share/prescription market share
change. This indicated that the physicians switched from
this category to other pharmacological class of antihypertensive medication. As for ACEI, due to its high leverage
clinical market share/prescription market share ratio, it
had a moderate prescription market share loss and a high
clinical market share loss. ACEI actually had the highest absolute and the second highest percentage DDDs/
prescription growth among all sub groups (Table 3).
These mixed signals indicated that while some physicians
may switch ACEI to other categories, some physicians
still rely more on ACEI to treat their patients. AIIA, even
though with higher prescription market share and clinical market share gains than CCB, had fluctuating pattern
and a minute loss on clinical market share/prescription
market share ratio. This may be due to the fact that AIIA
is still at the high growth phase. CCB is another prominent winner with triple positive gains on clinical market
share, prescription market share and clinical market
share/prescription market share ratio. This may be due to
the fact that CCB is in the slow growth phase.
It has been demonstrated that MC was the early
adaptor for AIIA and played an important role in the utilization diffusion of AIIA. The PT5%,PMS for AIIA at MC,
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RH, DH are 2 years, 2 years and 3 years and PT10%,PMS
for MC is 4 years. Prescription market required longer
penetration time than clinical market in all 4 different medical sectors. Judging from both market growth
momentum and penetration time parameters, it is apparent that size of the medical institution plays an important
role in the introduction phase of a new class of medication: the larger the institution, the stronger the market
momentum and the faster penetration would be.
V. Comparison of Prescribing Antihypertensive Agents in
Taiwan with International Guidelines
In the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure (7th US JNC), one of the key messages was “thiazide-type diuretics should be used in drug
treatment for most patients with uncomplicated hypertension, either alone or combined with drugs from other classes”(20). Similarly, the latest WHO guideline states that “for
the majority of patients without a compelling indication
for another class of drug, a low dose of a diuretic should
be considered as the first choice of therapy on the basis of
comparative trial data, availability and cost”(21). However,
our study indicated that current practice in Taiwan was
not in line with the international guidelines. The data of
prescription number in Table 2 implied that ß-blockers
were the predominant prescribed medication for antihypertensive management during 1997 to 2002 in Taiwan.
A study conducted by Cheng et al. at a MC in 2001 also
confirmed our observation that diuretics were not the drug
of choice for antihypertensive management. Instead calcium-channel blockers were most commonly used alone and
in general practices, despite the fact that they should be
used in second-line treatments(22).
VI. Limitation
This study was conducted based on the most recent
available claim data from the NHIRD. In general, health
resource allocation is better measured or evaluated by
financial amount rather than by volume serviced(9).
However, we tried to analyze the clinical unitization
of antihypertensive pharmaceutics through the volume
serviced via different point of view in this study. Pharmaceutical utilization pattern is influenced by multiple variables. Patients’ accessibility, patient population profile,
physician profile, hospital scale, introduction of new innovative chemical compound or generic products, pharmaceutical marketing effort toward physician or patient,
drug approval process, drug pricing and reimbursement policy, pattern of persistence in using medications,
number of prescribed medication classes, specific medication at enrollment etc. are just a few variables that interwoven together(23). Information regarding some of the
above factors is generally lacking or unable to be quantified. Other limitations for database studies include: data

quality, sources of bias, population characteristics, insufficient generalizability, cohort characteristics, and clinical outcomes(24). Some may also question our focus on a
process of care intervention (antihypertensive prescribing)
rather than clinical outcomes(3). It is important to note
that the claims database in this case merely represents the
final result of the time trend of the pharmaceutical quantity consumed and the number of prescriptions prescribed
in the “real world” environment. We could only try to
analyze these data through macroscopic point of view. We
did not attempt to disseminate all the factors that affect
the prescribing behavior. Only with this in mind will we
be able to gain more knowledge in this field.

CONCLUSIONS
The market share methodology allows us to differentiate the physicians’ prescribing pattern shift. The results
suggest that the introduction of AIIA did not consistently
affect the utilization of various antihypertensive drugs.
The clinical market shares of ß-blockers and miscellaneous
antihypertensive agents decreased from 1997 to 2002,
while the use of CCB and AIIA to control hypertension
increased. MC was the early adaptor for AIIA and played
an important role in the utilization diffusion of AIIA.
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